The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...
Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate ...
Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...
First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...
MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...
Telix Pharmaceuticals (NASDAQ:TLX) outlined its commercial imaging franchise, regulatory plans for two radiodiagnostic ...
Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided system that combines magnetic resonance imaging (MRI) with precise prostate ...
How this approach differs from standard care Previous studies have shown that, for patients with four or fewer brain tumors, stereotactic radiation—which uses focused beams of high-dose radiation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results